Lipid Metabolism Practice Questions

Q: Which of the following is not considered a "bad cholesterol"?

HDL. ### Explanation **Correct Answer: A. HDL** **Why HDL is the "Good Cholesterol":** High-Density Lipoprotein (HDL) is termed "good cholesterol" because of its role in **Reverse Cholesterol Transport**. It picks up excess cholesterol from peripheral tissues and blood vessel walls (including atherosclerotic plaques) and transports it back to the liver for excretion in bile. High levels of HDL are cardio-protective as they reduce the risk of atherosclerosis and coronary artery disease. **Why the other options are "Bad Cholesterol":** These lipoproteins are considered "bad" because they transport lipids from the liver to the peripheral tissues, contributing to plaque formation: * **LDL (Low-Density Lipoprotein):** The primary carrier of cholesterol to tissues. It is the most potent pro-atherogenic lipoprotein; high levels lead to cholesterol deposition in arterial walls. * **VLDL (Very Low-Density Lipoprotein):** Secreted by the liver to transport endogenous triglycerides. It is a precursor to LDL. * **IDL (Intermediate-Density Lipoprotein):** Formed during the conversion of VLDL to LDL. Like LDL, it is enriched in cholesterol esters and contributes to atherosclerosis. **High-Yield NEET-PG Pearls:** * **Apo-A1:** The primary apoprotein associated with **HDL** (activates LCAT). * **Apo-B100:** The characteristic apoprotein for **VLDL, IDL, and LDL**. * **LCAT (Lecithin-Cholesterol Acyltransferase):** The enzyme responsible for esterifying cholesterol within HDL, converting it from discoid to spherical form. * **Friedewald Formula:** Used to calculate LDL: $LDL = Total\ Cholesterol – (HDL + TG/5)$. (Note: This is invalid if TG >400 mg/dL).

Q: Hypertriglyceridemia is not a feature of which of the following conditions?

Alcoholism. **Explanation:** This question appears to have a technical error in its framing or key, as **Alcoholism, Obesity, Diabetes Mellitus, and Pregnancy are all classic causes of Hypertriglyceridemia.** However, in the context of standard medical examinations, if one must be excluded based on the *primary* lipid profile change or the *mechanism* of lipid elevation, the reasoning is as follows: 1. **Alcoholism (Correct Answer per key):** While chronic alcohol consumption typically **increases** VLDL and triglycerides (by increasing the NADH/NAD+ ratio, which promotes fatty acid synthesis), some examiners argue that its hallmark is fatty liver (steatosis) rather than isolated systemic hypertriglyceridemia, or they may be contrasting it with the more "direct" metabolic syndromes. *Note: Clinically, alcohol is a major cause of Type IV hyperlipidemia.* 2. **Obesity:** Strongly associated with hypertriglyceridemia. Increased adipose tissue leads to higher flux of free fatty acids to the liver, stimulating VLDL production. 3. **Diabetes Mellitus:** Insulin deficiency or resistance decreases the activity of **Lipoprotein Lipase (LPL)**. Since LPL is required to clear chylomicrons and VLDL, its deficiency leads to significant hypertriglyceridemia. 4. **Pregnancy:** A physiological state of hyperlipidemia. Estrogen increases VLDL synthesis, and insulin resistance in the third trimester decreases LPL activity to ensure nutrient availability for the fetus. **High-Yield Clinical Pearls for NEET-PG:** * **LPL Activator:** Insulin and Apo C-II. * **LPL Inhibitor:** Apo C-III and Angiopoietin-like protein 4. * **Eruptive Xanthomas:** Characteristic skin finding when serum triglycerides exceed 1000 mg/dL. * **Acute Pancreatitis:** A critical complication of severe hypertriglyceridemia. * **Alcohol's effect:** Increases NADH, leading to increased alpha-glycerophosphate, which provides the backbone for triglyceride synthesis.

Q: Which one of the following is of highest predictive value in the morbidity of coronary heart disease?

Apolipoprotein B. **Explanation:** **Apolipoprotein B (ApoB)** is considered the most accurate predictor of coronary heart disease (CHD) risk because it provides a direct measure of the total number of atherogenic particles. Each particle of VLDL, IDL, and LDL contains exactly **one molecule of ApoB-100**. While LDL-C measures the cholesterol *volume* within particles (which can vary), ApoB reflects the actual *particle count*. Since smaller, denser LDL particles are more prone to oxidation and arterial wall penetration, a high ApoB count indicates a higher "atherogenic burden," even if total LDL-C levels appear normal. **Analysis of Incorrect Options:** * **Low-Density Lipoprotein (LDL):** While traditionally used as the primary target for therapy, LDL-C can be misleading in patients with metabolic syndrome or diabetes who have small, dense LDL particles. ApoB has been shown in recent trials (like the INTERHEART study) to be a superior predictor compared to LDL-C. * **Lipoprotein (a) [Lp(a)]:** This is an independent genetic risk factor for CHD. While highly significant, it is not as strong a universal predictor of morbidity as the total ApoB count. * **Apolipoprotein A (ApoA-1):** This is the primary protein associated with HDL (the "good" cholesterol). A *low* level of ApoA-1 is associated with risk, but it is the **ApoB/ApoA-1 ratio** (rather than ApoA alone) that is a strong predictor. **High-Yield Clinical Pearls for NEET-PG:** * **ApoB-100** is found in VLDL, IDL, and LDL (liver-derived). * **ApoB-48** is found in Chylomicrons (intestine-derived). * **Friedewald Formula:** LDL = Total Cholesterol – [HDL + (Triglycerides/5)]. This formula is invalid if TG >400 mg/dL. * **ApoB/ApoA-1 ratio** is often cited as the single most important lipid parameter for predicting myocardial infarction risk.

Q: All of the following statements about fatty acid synthesis are true, except:

Palmitoleic acid is the end product. **Explanation:** The correct answer is **D**, as the primary end product of the fatty acid synthase (FAS) complex is **Palmitic acid (Palmitate)**, a 16-carbon saturated fatty acid. Palmitoleic acid is a monounsaturated fatty acid (16:1) formed later by desaturation in the endoplasmic reticulum. **Analysis of Options:** * **A. Occurs in cytosol:** This is true. Unlike fatty acid oxidation (which occurs in the mitochondria), synthesis takes place in the cytoplasm, primarily in the liver, lactating mammary glands, and adipose tissue. * **B. Citrate shuttle is required:** This is true. Acetyl CoA is produced in the mitochondria but cannot cross the inner mitochondrial membrane. It condenses with oxaloacetate to form **Citrate**, which is shuttled into the cytosol and cleaved back into Acetyl CoA and oxaloacetate by *ATP-citrate lyase*. * **C. Acetyl CoA is the immediate substrate:** This is true. Acetyl CoA serves as the initial primer and the building block (after conversion to Malonyl CoA) for the synthesis of the carbon chain. **High-Yield NEET-PG Pearls:** * **Rate-limiting enzyme:** Acetyl CoA Carboxylase (ACC), which requires **Biotin** (Vitamin B7) as a cofactor. * **Reductant:** **NADPH** is the essential electron donor, primarily supplied by the Hexose Monophosphate (HMP) Shunt. * **Multienzyme Complex:** In humans, Fatty Acid Synthase is a dimer with seven different catalytic activities on a single polypeptide chain, including the **Acyl Carrier Protein (ACP)** which contains Vitamin B5 (Pantothenic acid). * **Inhibitor:** Malonyl CoA inhibits *Carnitine Palmitoyltransferase-I (CPT-I)*, preventing simultaneous synthesis and degradation of fatty acids (preventing a futile cycle).

Q: Eicosapentaenoic acid is present in which of the following?

Fish oil. **Explanation:** **Eicosapentaenoic acid (EPA)** is a long-chain **Omega-3 (ω-3) polyunsaturated fatty acid (PUFA)** containing 20 carbons and five double bonds (20:5; Δ5,8,11,14,17). **Why Fish Oil is Correct:** The primary dietary sources of EPA and Docosahexaenoic acid (DHA) are **marine oils**, specifically fatty fish (e.g., salmon, mackerel, sardines) and fish oil supplements. These marine organisms accumulate EPA from the microalgae they consume. In humans, EPA serves as a precursor for **Series-3 prostaglandins** and **Series-5 leukotrienes**, which are generally anti-inflammatory and cardioprotective. **Why Other Options are Incorrect:** * **Soybean oil, Corn oil, and Safflower oil** are primarily rich in **Omega-6 (ω-6) fatty acids**, specifically **Linoleic acid** (18:2; Δ9,12). * While some plant oils (like flaxseed or soybean) contain the omega-3 fatty acid **Alpha-linolenic acid (ALA)**, the conversion of ALA to EPA in the human body is inefficient. Therefore, these oils are not considered direct sources of EPA. **High-Yield Clinical Pearls for NEET-PG:** * **Essential Fatty Acids (EFA):** Linoleic acid (ω-6) and Alpha-linolenic acid (ω-3) are "true" EFAs because humans lack the enzymes (Δ12 and Δ15 desaturases) to synthesize them. * **Cardiovascular Benefit:** EPA competes with Arachidonic acid for the enzyme Cyclooxygenase (COX). EPA produces **Thromboxane A3 (TXA3)**, which is a very weak platelet aggregator, thereby reducing the risk of intravascular thrombosis. * **DHA (22:6; ω-3):** Often found alongside EPA in fish oil; it is vital for retinal function and brain development in infants.

Q: Which of the following uses ketone bodies, except?

Hepatocytes. **Explanation:** The correct answer is **Hepatocytes (Option D)**. The utilization of ketone bodies (ketolysis) requires the enzyme **Thiophorase** (also known as Succinyl-CoA:3-ketoacid CoA transferase). While the liver is the primary site of **ketogenesis** (production of ketone bodies), it lacks the enzyme Thiophorase. Therefore, the liver can produce ketone bodies but cannot utilize them for energy, ensuring that ketone bodies are exported to peripheral tissues during starvation. **Analysis of other options:** * **Brain (Option A):** During prolonged starvation, the brain adapts to use ketone bodies (specifically 3-hydroxybutyrate and acetoacetate) as its primary energy source, meeting up to 75% of its energy requirements to spare glucose. * **RBCs (Option B):** This is a common point of confusion. **RBCs cannot use ketone bodies** because they lack mitochondria (ketolysis occurs in the mitochondrial matrix). However, in the context of this specific question, **Hepatocytes** is the most definitive answer regarding the specific absence of the enzyme Thiophorase. *Note: If both are options, Hepatocytes is the classical biochemical answer for "lack of enzyme."* * **Skeletal Muscles (Option C):** Extrahepatic tissues like skeletal and cardiac muscles are the primary consumers of ketone bodies during early starvation. **High-Yield Facts for NEET-PG:** 1. **Rate-limiting enzyme of Ketogenesis:** HMG-CoA Synthase (Mitochondrial). 2. **Organelle:** Ketogenesis and Ketolysis both occur in the **Mitochondria**. 3. **Ketone bodies:** Acetoacetate, 3-hydroxybutyrate, and Acetone (a non-metabolizable waste product). 4. **Key Deficiency:** Liver lacks **Thiophorase**, preventing a futile cycle.

Q: Hepatosplenomegaly with foam cells is characteristically seen in a lysosomal disorder. This disorder is due to the deficiency of which enzyme?

Sphingomyelinase. **Explanation:** The clinical presentation of **hepatosplenomegaly** combined with the presence of **foam cells** (lipid-laden macrophages) is the hallmark of **Niemann-Pick Disease (Types A and B)**. This autosomal recessive lysosomal storage disorder is caused by a deficiency of the enzyme **Sphingomyelinase**, leading to the accumulation of sphingomyelin within the lysosomes of the reticuloendothelial system. **Analysis of Options:** * **A. Sphingomyelinase (Correct):** Its deficiency leads to Niemann-Pick Disease. The characteristic "foam cells" are macrophages with a "mulberry" or soap-bubble appearance due to accumulated sphingomyelin. * **B. Hexosaminidase A:** Deficiency causes **Tay-Sachs Disease**. While it features a cherry-red spot on the macula, it is distinguished by the **absence** of hepatosplenomegaly. * **C. Beta-galactosidase:** Deficiency causes **Krabbé disease** (characterized by globoid cells and demyelination) or **GM1 gangliosidosis**. * **D. Beta-glucosidase (Glucocerebrosidase):** Deficiency causes **Gaucher Disease**. While it also presents with hepatosplenomegaly, the characteristic cells are **Gaucher cells** (described as "wrinkled tissue paper" or "crumpled silk" appearance), not foam cells. **NEET-PG High-Yield Pearls:** * **Niemann-Pick vs. Tay-Sachs:** Both can have a **cherry-red spot**, but only Niemann-Pick has **hepatosplenomegaly**. * **Mnemonic:** "No-man Picks (Niemann-Pick) his nose with his **Foamy** finger." * **Zebra Bodies:** Electron microscopy in Niemann-Pick shows lamellated cytosolic inclusions called zebra bodies. * **Type A vs. B:** Type A is the infantile, neuropathic form; Type B presents later with no CNS involvement.

Q: In the well-fed state, what inhibits the activity of Carnitine Palmitoyl Transferase-1 located in the outer mitochondrial membrane?

Malonyl-CoA. **Explanation:** The correct answer is **Malonyl-CoA**. This is a classic example of metabolic regulation designed to prevent a "futile cycle" (simultaneous synthesis and breakdown of fatty acids). **1. Why Malonyl-CoA is correct:** In the **well-fed state**, insulin levels are high, leading to increased fatty acid synthesis in the cytosol. The first committed step of lipogenesis is the conversion of Acetyl-CoA to Malonyl-CoA by the enzyme *Acetyl-CoA Carboxylase (ACC)*. **Malonyl-CoA** acts as a potent allosteric inhibitor of **Carnitine Palmitoyl Transferase-1 (CPT-1)**. By inhibiting CPT-1, Malonyl-CoA prevents the transport of long-chain fatty acids into the mitochondria for β-oxidation. This ensures that while the body is actively synthesizing fat, it is not simultaneously burning it. **2. Why other options are incorrect:** * **Glucose:** While high glucose levels trigger the insulin release that leads to Malonyl-CoA production, glucose itself does not directly bind to or inhibit CPT-1. * **Acetyl-CoA:** This is a precursor for both the TCA cycle and lipogenesis. While it is used to form Malonyl-CoA, it does not directly inhibit CPT-1. * **Pyruvate:** Pyruvate is the end-product of glycolysis. It enters the mitochondria to be converted into Acetyl-CoA but has no direct regulatory effect on the carnitine shuttle. **High-Yield Clinical Pearls for NEET-PG:** * **CPT-1 Location:** It is located on the **outer** mitochondrial membrane, whereas CPT-2 is on the inner membrane. * **Rate-Limiting Step:** CPT-1 is the rate-limiting step for **β-oxidation** of fatty acids. * **Deficiency:** CPT-1 deficiency typically presents as non-ketotic hypoglycemia and hepatomegaly, often triggered by fasting. * **Key Concept:** Insulin → Stimulates ACC → ↑ Malonyl-CoA → Inhibits CPT-1 → ↓ Fatty acid oxidation.

Question 1

Which of the following is not considered a "bad cholesterol"?

Accepted Answer

HDL

Answer

LDL

Answer

VLDL

Answer

IDL

Question 2

In diabetics, what factor limits the synthesis of triglycerides in adipose tissue?

Accepted Answer

Glycerol-3-P

Answer

NADPH

Answer

ATP

Answer

Acetyl CoA

Question 3

A child presented with altered sensorium and icterus three days after a viral illness for which he was treated with aspirin. What is the underlying biochemical defect?

Accepted Answer

Beta oxidation of fatty acids

Answer

Glucose-6-phosphatase deficiency

Answer

Pyruvate dehydrogenase deficiency

Answer

Urea cycle defect

Question 4

Hypertriglyceridemia is not a feature of which of the following conditions?

Accepted Answer

Alcoholism

Answer

Obesity

Answer

Diabetes mellitus

Answer

Pregnancy

Question 5

Which one of the following is of highest predictive value in the morbidity of coronary heart disease?

Accepted Answer

Apolipoprotein B

Answer

Lipoprotein A

Answer

Apolipoprotein A

Answer

Low density lipoprotein

Question 6

All of the following statements about fatty acid synthesis are true, except:

Accepted Answer

Palmitoleic acid is the end product

Answer

Occurs in cytosol

Answer

Citrate shuttle is required

Answer

Acetyl CoA is the immediate substrate

Question 7

Eicosapentaenoic acid is present in which of the following?

Accepted Answer

Fish oil

Answer

Soybean oil

Answer

Corn oil

Answer

Safflower oil

Question 8

Which of the following uses ketone bodies, except?

Accepted Answer

Hepatocytes

Answer

Brain

Answer

RBCs

Answer

Skeletal muscles

Question 9

Hepatosplenomegaly with foam cells is characteristically seen in a lysosomal disorder. This disorder is due to the deficiency of which enzyme?

Accepted Answer

Sphingomyelinase

Answer

Hexosaminidase

Answer

Beta-galactosidase

Answer

Beta-glucosidase

Question 10

In the well-fed state, what inhibits the activity of Carnitine Palmitoyl Transferase-1 located in the outer mitochondrial membrane?

Accepted Answer

Malonyl-CoA

Answer

Glucose

Answer

Acetyl-CoA

Answer

Pyruvate

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?